Life Sciences Archive » March, 2012

Life Sciences - March, 2012

255 articles

• Prometheus To Wreak Vast Patent Turmoil, Experts Say
• Baker & McKenzie Snags Expert IP Litigator From Torys
• Ex-Novartis Consultant's FCA Retaliation Suit Stays Alive
• Ista Investor Sues To Block $500M Bausch & Lomb Deal
• FDA User Fee Bill Eyes Drug Shortages, New Antibiotics
• Investor Class Certified On Claims Pfizer Masked Drug Risks
• Judge Says Apotex Generic Doesn't Infringe Cephalon Patent
• AstraZeneca's Seroquel XR Ruled Valid And Infringed
• Case Study: Hermelin V. KV Pharmaceutical
• FDA Panel Says Obesity Drugs Need Tougher Clinical Trials
• Pfizer Urges JPML To Combine Zoloft Cases In NY
• Lambda Says Gay Juror's Dismissal Illegal In GSK-Abbott Row
• FDA To Give Drugmakers Leeway On ACA Reporting Deadline
• Sens. Warn Colleagues Not To Derail FDA User Fee Bill
• Volcano Owes Subsidiary's Shareholders $27M, Suit Says
• Novartis Settles Kentucky Drug-Pricing Claims For $3M
• Judge Denies AstraZeneca's Seroquel Challenge But Blasts FDA
• Horizon Tries To Thwart Par's Plans For Arthritis Generic
• Roche Bumps Illumina Cash Offer Up To $6.5B
• New Safety Worries Spark FDA Scrutiny Of Metal Hip Implants
• Searching For Patent Drafting Pointers In Prometheus
• States' Medicaid Coercion Argument Sways Some Justices
• FDA Could Make Generics Liable Amid Push To Undo Mensing
• Justices Divided On Power To Scrap Entire Health Care Law
• Judge Again Tosses Abbott Patent For Inequitable Conduct
• AstraZeneca Sues FDA As Firms Debut Generic Seroquel
• Cypress Pays $2.8M To Settle FCA Suit Over Unapproved Drugs
• Merchant & Gould Brings Biotech Patent Pair To Denver
• Fed. Circ. Orders Arbitration In Gene Test Royalty Row
• FDA Revises Celexa Warnings Over Heart Disorder Risk
• Covidien Doesn't Infringe Surgical Seal Patent, Judge Says
• Ratting Out The Competition: New DOJ Strategies
• Must-Have Performance Metrics For Law Departments
• GE, Cardinal Accused Of Manipulating Cardiac Imaging Market
• High Court's Take On Health Market Key To ACA Decision
• Bipartisan Senate Bill Aims To Hasten Key Drug Approvals
• Cetero Gets Nod To Borrow $2.4M To Fund Ch. 11 Sale
• FDA Sheds Light On Medical Device Risk Reviews
• Lawmakers Vow Health Law Repeal If High Court Lets It Stand
• Biotronik Wants $100M Suit Over J&J Stent Recall Reopened
• Bioethics Panel Seeks Input On Genome Privacy Issues
• Judge Approves $158M Settlement Of J&J Risperdal Suit
• Understanding Christopher V. SmithKline
• Merck Suit To Bar Ky. AG From Hiring Outside Attys Kept Alive
• Glaxo Settles Cancer Treatment IP Skirmish With Genentech
• Bill Would Allow Labeling Suits Against Generics Cos.
• Medical Device Makers Claim $20B Tax Will Hurt Jobs
• Syringe Maker Brings Claim Construction Feud To High Court
• Petition Over Prempro Injury Suits Turned Down By High Court
• AstraZeneca Can't Get FDA Tip-Off On Generic Approvals
• J&J Questions $158M Settlement Of Texas' Risperdal Suit
• Roche Again Extends $5.7B Offer To Illumina Shareholders
• FDA Considers Changes To Obesity Drug Clinical Trials
• High Court Health Reform Battle Focuses On Tax Law
• Healthpoint Stuck In $90M Medicaid Fraud Suit
• Automated Infusion Patent Claims Toothless, Fed. Circ. Finds
• Pa. High Court Rules J&J Not Liable In Surgery Death
• High Court Sends Myriad Gene Patent Row Back To Fed. Circ.
• Supreme Court Blocks Apotex Glaucoma Drug Invalidity Appeal
• Columbia Sues Illumina Over DNA Mapping Patents
• Pharmaceutical Industry Trending Toward Self-Regulation
• Biomet Inks $23M Deal In Latest Doctor Bribery Sting
• AstraZeneca Can't Prevent FDA Approval Of Generic Seroquel
• Roche Gets New Look On Timeliness Of Accutane Case
• Drug Claims Violate FCA, Ex-Pfizer Exec Tells 1st Circ.
• Tracking Foreign Direct Investment In Ireland
• Health Care Reform Faces Ultimate Test In High Court
• Zoll Shareholder Files Class Action Over $2B Asahi Sale
• Doctors Urge Over-The-Counter Birth Control At FDA Hearing
• USPTO Tells Examiners How To Apply Prometheus Ruling
• EUSA Pharma To Pay $180K Over Inflated Medicare Claims
• Merck Loses Challenge To Private Vioxx Prosecution
• Pfizer Can't Shake Fraud Suit Over Risky Arthritis Drugs
• Experts Say FDA Ignored Evidence In High-Dose Aricept Review
• False Marking Changes Unconstitutional, Group Says
• Covidien To Shell Out $108M For Ventilator Maker
• FDA Ordered To Target Antibiotics In Animal Feed
• BPA's Expiration Date May Be On Its Way
• DC Circ. Renews CVS Pharmacies' Controlled Drug Sales Ban
• Genzyme Tops Cobrek In Kidney Drug Patent Fight
• UK Court Invalidates AstraZeneca's Seroquel XR Patent
• Judge Trims Expert Testimony In Novartis Bone Drug Suit
• High Court Asked To Reinstate $26M Merck Vioxx Judgment
• More Inspiration From The Courts On Commercial Speech
• Fed. Circ. Axes Sanofi IP Claims Over Genentech Cancer Drugs
• House Votes To Nix Medicare Cost-Cutting Board
• Husch Blackwell Picks Up Duane Morris Patent Pro
• Wash. Takes Emergency Contraceptives Ruling To 9th Circ.
• Stryker's Wingspan Stent May Raise Stroke Risk, FDA Says
• Justices' Questions May Signal Health Mandate's Fate
• Pharmacies Targeted In Probe Of Gray-Market Drug Sales
• Stakeholders To Weigh In On Making More Drugs OTC
• Weil Expands Into NJ With Princeton Office
• GOP Zeroes In On Agency Implementing Health Care Law
• Judge Tosses Calif. County's Vioxx Class Action
• Fewer Life Sciences Co. Investor Suits Lodged In 2011
• DC Circ. Says ViroPharma Can't Sue FDA Over Generics Ruling
• GSK, J&J Back New $198.5M Incubator Fund
• Expanding The 'Quick Look' Framework
• Skowron To Pay Morgan Stanley $10.2M For Stock Dump
• Roche Urges Illumina Shareholders To Spur $6B Merger
• Canada Places Cancer Warnings On Merck And GSK Drugs
• Dissecting Mayo V. Prometheus
• Waxman Pressures FTC On $29B Express Scripts, Medco Deal
• Rising Star: King & Spalding's Marian Lee
• Pfizer To Pay Oregon $3.3M To End Zyvox Marketing Suit
• Foley Scores Former White House International IP Guru
• Judge Tainted $60M Trademark Row, NuVasive Tells 9th Circ.
• OTC Drugmaker Says BioZone Breached Cold Meds Contract
• Case Study: Abbott Point Of Care V. Epocal
• Prometheus Blood Test Unpatentable, High Court Rules
• GSK Asks High Court To Buck DOL On Sales Reps' OT Status
• Mylan, Apotex Secure FDA Approval For Generic Boniva
• Rising Stars: Hunton & Williams' Colleen Heisey
• FDA Recalls Brilliant Blue G After Eye Infection Reports
• Mercer Consultant Pleads Guilty To Insider Trading
• Tax Code Ruling Could Leave Health Reform Law In Limbo
• FTC Urged To Probe Merck, Sanofi Vaccine Bundling
• Judge Clears Feds For Withholding Generic Vancocin Docs
• Presenting ... A Fresh Interpretation Of Old Policy
• Covidien Shells Out $300M For Israeli Medical Device Maker
• Novartis Bone Drug Action Doomed By Statute Of Limitations
• Eisai Says Sanofi Misled Court In Feud Over Deposition Docs
• Obama Admin Floats Proposals On Contraception Rules
• Baxter Scores $24M Judgment In Fresenius Patent Suit
• DC Circ. Revives Cardinal Shipping Ban In Oxycodone Fight
• High Court Vows Same-Day Audio Of Health Care Debate
• Sens. Push For Stalled FDA Rule On Device ID System
• Genzyme Targets InvaGen Over Kidney Treatment Generics
• Jury Rules In Favor Of Carl Zeiss In Lens Patent Suit
• Synthes, Stryker Settle Trade Secrets Suit Over Sales Reps
• Case Study: Bristol-Myers V. Kappos
• Sanofi Acquires Pluromed To Commercialize Surgical Gel
• Impax Can't Shake Injunction On Generic Amrix
• Bipartisanship Breaks Down Behind Medicare Board Repeal
• GSK Strikes $613M Deal With Omega For OTC Brands, Plant
• Sanofi Asks Fed. Circ. To Upset Dr. Reddy's Allegra Patent Win
• Consultant Cops To Insider Trading On Carlyle's NBTY Buy
• CVS Caremark Says No Wrongdoing Alleged In FCA Suit
• Shire Inks $325M Deal For Blood Disorder Drug Co.
• Guidant Can't Kill $726M FCA Suit Over Implant Claims
• Biotech Co. Sues Sandoz Over Remodulin Generic
• Shire Pulls US Drug Application, Blames FDA Delay
• Albemarle Loses Bid To Toss EPA Clean Air Act Suit
• The Ever-Broadening Reach Of Dukes
• Trends In White Collar Crime Investigations, Prosecutions
• Professor Seeks FDA Probe Into Stem Cell Cos.' Practices
• Faruqi Firm Won't Get Lead Role In Roche Takeover Action
• Microsoft Revises Privacy Policy To Reflect Targeted Health Ads
• DC Circ. Lifts CVS Pharmacies' Prescription Sale Ban
• Roche Loses Bid To Block Generic Boniva
• Teva Gets FDA Green Light For 1st Lexapro Generic
• HHS Loosens Oversight Of Medicare Equipment Suppliers
• Judge Slashes Ex-Omeros Exec's FCA Suit Over NIH Grants
• Forest Labs Starts Patent Battle Over Beta-Blocker
• Pay For Delay, There For The Taking?
• The Uncertainty Of Medicaid Entitlement Enforcement
• UK Medical Journal Invokes Anti-SLAPP Law In Libel Suit
• FTC Seeks More Info From Roche On $6B Illumina Takeover
• Pfizer Won't Get To Trim BYU's Bextra-Celebrex Suit
• Boston Scientific Award Upped To $42M In Cordis Stent IP War
• Roche Unit Loses In Arbitration Over Merger Of Medical Cos.
• Precision BioSciences Expands Patent War Against Cellectis
• DC Circ. Foils Bid To Ban Mercury-Containing Vaccines
• Texas Hospital Dodges $30M FCA Suit Over Drug Supplies
• Some Warner Chilcott Birth Control May Not Work, FDA Warns
• AstraZeneca Sues FDA Over Generic Seroquel Labels
• Express Scripts, Medco Delay Deal Pending FTC Review
• Medtronic Investors Sue Over $3B Inflated Stock Buyback
• Sandoz, Others Escape Faulty Painkiller Patch Case
• China Places Strict Rules On Western Digital, Hitachi Merger
• USAA Scoops Up Stake In Real Estate Investor Square Mile
• Japanese Health Giant Snaps Up Device Maker For $2.2B
• Bayer Must Allow Cancer Generic In India, Court Rules
• FDA To Review TV Drug Ads Before Broadcast
• Calif. County Wants Claims Cut Loose From Plasma MDL
• GSK Skirts FCA Suit Over Physician Kickback Program
• J&J Unit's Stelara Infringes Abbott Patents, Judge Rules
• FTC Asks Pharm Groups How To Fix $29B Express Scripts Deal
• Why Communications Is Key To Merger And Lateral Success
• Drugmaker Bryan Corp. Sues Supplier Over Ingredient Quality
• FDA Moves To Improve Tracking Of Drug Safety Issues
• FDA Approves Third Silicone Gel Breast Implant
• Vitamin C Antitrust MDL Headed For October Trial
• FDA Rebuffs AstraZeneca's Bid To Delay Generic Seroquel
• Biotech Industry Sees Dollar Signs In Jobs Bill
• Lilly, Zydus Settle ADHD Generic Infringement Case
• Sens. Probe Role Of Rite Aid Wellness Ambassadors
• Azur, Avanir Push To Arbitrate $35M FazaClo Feud
• Health Care Is Undergoing Major Surgery In 2012
• Ex-Partner Goes After Troutman In $520M Malpractice Suit
• GSK Seeks High Court Input On IP Safe-Harbor Rule
• Latham & Watkins Reps Boston Scientific In $1.3B Deal
• Add-Ons To Drug User Fee Law Hit FDA Opposition
• Limbaugh Backlash Sparks Fight Over Concentra Name
• Chadbourne Atty Can't Stop Apartment Roof Garden
• Tackling 'Pay-For-Delay' In Calif. Supreme Court
• The Interplay Between FDA Approval And Discovery Rule
• Rebuttal: If It Ain't Broke ...
• AstraZeneca Sues Mylan Over Nexium Patents
• Judge Blocks Rival Botox Drug In Trade Secrets Trial
• Google Ordered To Dispense Canadian Pharmacy Ad Docs
• Investor Fights Illumina's Poison Pill Against Roche Bid
• Takeda Hid Diabetes Drug's Heart Risks, Ex-Reviewer Says
• Senate OKs Bill To Beef Up Counterfeit Drug Penalties
• Pfizer, Others Sued By Health Plans Over Copay Coupons
• Amgen Seeks High Court Review Of Investor Class Cert.
• Boiron To Pay Up To $12M To End False Advertising Suits
• Enzo Targets Abbott, Others Over DNA Testing Patents
• US Collected $509M FCPA Fines In 2011: Report
• GOP Lawmakers Scrutinize Low-Cost Drug Program
• 11th Circ. Limits Contribution Claims Under CERCLA
• J&J Unit In Hot Seat Over Pfizer ThermaCare IP
• Lawmakers Demand Info On Agencies' Email Monitoring Rules
• Medtronic Had Burden In Device IP Suit, Fed Circ. Told
• Reed Smith Guides Domain In $760M Venture With Rusnano
• Coventry, Policyholders Agree To $3.3M Deal Over Copays
• AeroShot Caffeine Inhaler Scrutinized By FDA
• FDA Finds Multiple Quality Violations At Synthes Plant
• Avanir Targets Watson In Suit Over Nuedexta Patents
• Premerger Plans Aren't Anti-Competitive: Calif. Court
• DC Circ. Lifts Shipping Ban On Cardinal Health
• Mensing Shields Generics Makers In Sprawling Darvocet MDL
• Immucor To Pay $22M To Stanch Blood Test Antitrust Action
• Doctors Bash Plan To Fight Rx Abuse By Denying Claims
• Zingers Fly As House Closes In On Medicare Board Repeal
• Ex-FDA Chemist Gets 5 Years For Insider Trading
• FDA Rejects Merck's Combo Cholesterol Drug For Now
• Novo Nordisk Faces $70M Sales Rep OT Action
• A Cloak Of Invisibility Is A 'Don't' In The Courtroom
• Eliminating A Standing Requirement Under Calif. UCL, FAL
• UK Biotech Co. Abcam Expands With $170M Epitomics Buy
• BP Settlement Dwarfs Top Product, Toxic Tort Deals
• DaVita Can't Escape FCA Suit Over Kidney Med Charges
• Sunovion Knocks Out 5 Patents In Mylan's Brovana Suit
• Invisalign Maker Tells ITC Rival's Imports Infringe Patents
• Millennium Labs Wants Rival's Attys Booted For Misconduct
• Merck Action Didn't Stop The Clock, Va. High Court Says
• Law360 Life Sciences Editorial Advisory Board
• Law360 Health Editorial Advisory Board
• Perkins Coie Nabs Health Team For New Practice Group
• Law360 Intellectual Property Editorial Advisory Board
• GSK Shakes EU Scrutiny In Generics Delay Probe
• How CMS Plans To Recoup Medicare, Medicaid Overpayments
• New Drug Co. Ethics Rules Focus On Doctor Relations
• Jury Sides With Pfizer Unit In Prempro Breast Cancer Case
• HHS' Sebelius Under Fire Over Contraception Rules
• FDA Warns Of 2 Hazardous Chemicals Used In Drugs
• Pfizer, Apotex End Patent Fight Over Generic Lipitor
• FDA Delays Approval Of Pfizer-BMS Anti-Clotting Drug
• Reglan Failure-To-Warn Suit Brought To Supreme Court
• Cardinal Health Painkiller Shipment Suspension Upheld
• Investor Objections Can't Halt Amgen's $1.2B Micromet Buy
• Pfizer Asks High Court To Scrap Novartis Hemophilia Patents
• EU Kills Generics Delay Probe Of AstraZeneca, Nycomed